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Abstract
 .  .Phosphatidylserine PS containing a 7-nitrobenz-2-oxa-1,3-diazol-4-yl- NBD- hexanoyl residue, like native PS,
preferentially distributes into the inner membrane leaflet of human erythrocytes. In the case of NBD-PS, this preference
results from two opposite active processes, an inward translocation mediated by the aminophospholipid flippase and an
outward translocation mediated by an ill-defined floppase. Selective inhibition of this floppase by alkylating reagents or
cationic and anionic drugs increases the extent of accumulation of NBD-PS in the inner membrane leaflet from about 70%
in control cells to about 90%. Different inhibitor sensitivities of the flippase and the floppase strongly suggest that both
represent different entities. The floppase was characterized in further detail by comparing inhibitory effects of various
compounds on this translocase with their effects on known primary active transport systems for amphiphilic compounds.
The inhibitory effects of various drugs, glutathione conjugates and GSSG on the floppase activity closely correlate with
 .those reported for the active transport by the multidrug resistance protein MRP while only poorly going parallel with those
for the active transport by the low affinity pump for glutathione conjugates and the multidrug resistance MDR1
P-glycoprotein. The NBD-phospholipid floppase activity of the erythrocyte is thus probably a function of MRP. q 1998
Elsevier Science B.V. All rights reserved.
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1. Introduction
 .The inward translocation flip of phosphatidylser-
 .  .ine PS and phosphatidylethanolamine PE from the
outer to the inner membrane leaflet of many plasma
membranes is a fast, active process mediated by a
w xflippase 1 , meaning that the head group of the
phospholipid approaches the binding site on the
transporter from the lipid domain instead of the usual
access of hydrophilic substrates from the aqueous
w xmedium 2 . This flippase has a high substrate speci-
ficity and only translocates the aminophospholipids,
w x 2qPE and PS 1 . It is a 115 kDa Mg -dependent
w xATPase II that has been cloned recently 3 . In ery-
throcytes, protein mediation as well as Mg2q and
ATP dependence have also been reported for the
 .outward translocation flop of newly synthesized PC
w x w x4 , inner leaflet phospholipid species 5,6 and a
w xvariety of anionic phospholipid probes 7 . This flop-
pase activity for phospholipid probes containing a
 .7-nitrobenz-2-oxa-1,3-diazol-4-yl- NBD- hexanoyl
w xresidue exhibits a low head group specificity 7 and
has a considerably higher activation energy 104 kJ
y1 w x.  y1 w x.mol 7 than the flippase 31 kJ mol 8 , which
indicates the involvement of different mechanisms.
Further protein-mediated passive translocation
pathways for phospholipid probes in erythrocytes
concern the Ca2q-dependent outward translocation of
w xphospholipids 9 mediated by a 37 kDa protein that
w xhas been cloned recently 10 as well as the inward
and outward translocation of mono- and di-anionic
NBD-labeled phospholipids and long-chain am-
 .phiphilic anions, 5- N-decyl aminonaphtalene-2-
 .sulfonate and 10- a-naphtyl -decyl-1-phosphate via
w xthe anion exchanger, band 3 protein 7,11–13 . In the
latter case, a classical transporter that binds its sub-
strate from the water phase also acts as a flippase that
has to bind its substrate from the lipid phase because
of very high membranerwater partition coefficients
w xfor these lipid probes 11–13 .
In the present study, the floppase activity of the
erythrocyte membrane was characterized functionally
by comparing inhibitory effects of alkylating reagents
and noncovalent inhibitors on this transporter with
their effects on various other active transport systems
for amphiphilic compounds, such as the aminophos-
pholipid flippase, the glutathione conjugate trans-
w xporters in the erythrocyte membrane 14–16 and the
transporters responsible for drug resistance, i.e., the
 w x.multidrug resistance protein MRP 17,18 , which
has recently identified in the erythrocyte membrane
w x w x17 , and the MDR1 P-glycoprotein 19–22 .
2. Materials and methods
2.1. Materials
Erythrocyte concentrates were obtained from the
local blood bank and used within 10 days. Erythro-
cytes were isolated by centrifugation and washed
three times with isotonic saline. The incubation
 .  y1.medium KNPS, pH 7.4 contained mmol l : KCl
 .  .  .  .90 , NaCl 45 , phosphate 12.5 and sucrose 44 .
w 1-Oleoyl-2- N- 7-nitrobenz-2-oxa-1,3-diazol-4-
. xyl aminohexanoyl -sn-glycero-3-phosphocholine
 . w 18:1,6-NBD-PC and 1-myristoyl-2- N- 7-nitro-
. xbenz-2-oxa-1,3-diazol-4-yl aminolauroyl -sn-glycero-
 .3-phosphocholine 14:0,12-NBD-PC were obtained
 .from Avanti Polar Lipids Alabaster, AL , dipyri-
damole, monensin, vinblastine, vincristine,
oligomycin, daunomycin, staurosporine, indo-
methacin, quinidine, genistein, benzbromarone,
prostaglandin A1, carbonyl cyanide m-chlorophenyl-
 .hydrazone CCCP , Triton X-100, 1-chloro-2,4-di-
 . w xnitrobenzene CDNB , L-1-chloro-3- 4-tosylamido -
 . w4-phenyl-2-butanone TPCK , L-1-chloro-3- 4-tosyl-
x  .amido -7-amino-2-heptanone TLCK , p-chloro-
 .mercuriphenylsulfonate PCMBS and ethacrynic acid
 .were from Sigma Deisenhofen , colchicine and
 .phloretin were from Roth Karlsruhe , salicylic acid
 .was from Merck Darmstadt , rose bengal was from
 .  .Fluka Neu-Ulm and verapamil Isoptin was from
 .Knoll Ludwigshafen . 2,4-Dinitrophenyl-S-gluta-
 .thione DNP-SG and the glutathione conjugate of
 .ethacrynic acid EA-SG were prepared according to
w xSaxena and Henderson 23 . NBD-labeled phos-
 .phatidylserine PS was prepared by transphospha-
tidylation of NBD-PC using phospholipase D as de-
w xscribed before 7 . The leukotriene D receptor antag-4
w xonist MK 571 24 was kindly provided by Dr. A.W.
Ford-Hutchinson Merck Frosst Centre for Therapeu-
.tic Research, Pointe Claire-Dorval, Quebec, Canada .
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2.2. Methods
2.2.1. Modification of erythrocytes
Erythrocytes were pretreated at 378C with 0.03–1.0
y1  . y1mmol l CDNB 30 min , 0.2 mmol l TPCK, 0.5
y1  . y1mmol l TLCK 15 min or 0.1 mmol l PCMBS
 .5 min in KNPS followed by two washes with 0.2 g
dly1 albumin in KNPS and two washes with KNPS.
( )2.2.2. Measurement of the inward translocation flip
of NBD-PS
After insertion of trace amounts of fluorescent
 y1 .NBD-phospholipid 8 nmol ml packed cells into
the outer membrane leaflet of erythrocytes 7 min,
.08C , cells were washed once, resuspended in KNPS
 .hematocrit 10% and incubated at 378C. The time-
dependent flip of the NBD-phospholipid to the inner
membrane leaflet was measured by following the
increase of fluorescence in the inner membrane leaflet,
w xF , using the albumin extraction procedure 7 . Briefly,i
at various time periods 100 ml samples of the suspen-
sion were mixed with 550 ml medium containing 1.5
y1  .g dl albumin and incubated 2 min, 218C . After
centrifugation, the albumin extraction was repeated
once and cells washed with KNPS. Subsequently,
cells were hemolyzed with 100 ml of water, lipids
extracted by addition of 800 ml of isopropanol and
the extract centrifuged. The fluorescence in the ex-
w xtracts was determined as described before 7 . The
fluorescence in the inner leaflet was related to the
total isopropanol-extractable fluorescence, F , in thetot
same amount of hemolyzed cells. An exponential
w  .xfunction, q 1yexp yk P trq , was fitted to the1
 .kinetic data of the non-extractable fractions F rF ,i tot
where q represents the fraction of probe in the inner
leaflet under stationary conditions and k the rate1
constant for the unidirectional flip.
2.2.3. Measurement of the outward translocation
( )flop of NBD-phospholipids
Following insertion of 15–20 nmol of NBD-phos-
pholipid mly1 packed cells and a flip period at 378C
of 45 min for NBD-PS, 90 min for 18:1,6-NBD-PC
 y1in the presence of 1 mol l ethanol to reversibly
w x.enhance its slow accumulation in the inner leaflet 7
and 120 min for 14:0,12-NBD-PC, the probe was
removed from the outer leaflet by two repetitive
 .extractions 2 min, 218C with 20 volumes of KNPS
 y1.containing albumin 1.5 g dl . After washing of the
cells with KNPS to remove albumin, the flop of the
NBD-phospholipid at 378C was followed by measur-
ing the time-dependent decrease of fluorescence in
w xthe inner leaflet 7 using two methods. In the first
method, the probe was allowed to equilibrate between
 .the two membrane leaflets 378C , i.e., the probe
moves to the outer leaflet with a rate constant, k ,y1
for the unidirectional flop and reaches a steady-state
distribution between the two membrane leaflets with
q the fraction of probe in the inner membrane leaflet
 .under stationary conditions equilibrative flop . To
measure this flop, the time-dependent decrease of the
probe in the inner leaflet was determined by two
repetitive albumin extractions of 100-ml samples of
the cell suspension as described above for the flip.
 . w An exponential curve, 1yq Pexp yk P tr 1yy1
.xq qq, was fitted to the kinetic data of the non-ex-
 .tractable fractions F rF .i tot
In the second method, the flop was measured at
378C in the presence of 0.75 g dly1 albumin in the
 .medium 1.5% hematocrit , which continuously re-
moves the probe from the outer membrane leaflet
 .zero-trans flop . To this end, 750 ml samples of the
cell suspension were centrifuged at various time peri-
ods of flop, cells were washed once with KNPS and
lipids extracted to determine fluorescence. In this
case q was set to zero.
2.2.4. Preparation of resealed ghosts and flop mea-
surement
After insertion of the NBD-phospholipid probe
into the membrane, 1 volume of erythrocytes was
 .hemolyzed in 10 volumes of water 08C containing
 y1.  y1.GSH 4–8 mmol l and ouabain 0.1 mmol l . In
certain preparations, DNP-SG, EA-SG or GSSG was
present in the hemolyzing solution. Subsequently,
 y1ATP and MgCl 3–5 mmol l , final concentra-2
.tions were added and the hemolysate incubated for
10 min, followed by KCl final concentration 150
y1 .mmol l , 10 min 08C . Ghosts were then resealed by
 .incubation 15 min at 378C. Resealed ghosts were
washed three times with KNPS. Following extraction
of the phospholipid probe from the outer membrane
leaflet by albumin, the flop was measured as de-
scribed above for erythrocytes. The concentrations of
DNP-SG and GSH within the resealed ghosts were
determined after lysis of the ghosts, protein denatura-
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tion and centrifugation by measuring the absorption
of the supernatant at resp. 340 nm in absence and 413
 .nm in presence of 5,5-dithio-bis 2-nitrobenzoic acid .
2.2.5. Measurement of the outward transport of glu-
tathione conjugates
Efflux of 2,4-dinitrophenyl-S-glutathione DNP-
. w xSG was measured according to Ref. 25 . Cells were
 . y1pretreated 30 min, 378C with 1 mmol l CDNB to
convert GSH to DNP-SG, washed two times with
KNPS containing 0.2 g dly1 albumin and three times
with KNPS. Subsequently, 1 volume of packed cells
was resuspended in three volumes of KNPS and
incubated at 378C. At different time intervals, cell
samples were sedimented by centrifugation and the
supernatant was deproteinized by addition of HClO4
followed by centrifugation. The amount of released
 .2,4-dinitrophenyl glutathione DNP-SG was then
measured by the increase of the absorption of the
supernatant at 340 nm.
3. Results and discussion
w xIn previous studies on human erythrocytes 26 , it
has been shown that the rate of inward translocation
 .  .flip of a fluorescent PS containing a 6- NBD amino
hexanoyl residue at the 2-position of glycerol is
slower than that of a spin-labeled PS probe with a
w x4-doxylpentanoyl residue 26 . Moreover, the station-
ary distribution of this NBD-PS proved to be signifi-
 w x.cantly lower somewhat below 80% inside 26 than
 w x.that of the spin-labeled PS 95% inside 26 and
 w x.endogenous PS 100% inside 27 . According to
w xrecent results from our laboratory 7,28 , the station-
ary level of NBD-PS in the inner leaflet probably
results from two opposite processes, an active inward
translocation mediated by the aminophospholipid
flippase and an outward translocation mediated by a
 2q .Mg , ATP -dependent floppase. In the present
study, this concept was examined further and a func-
tional characterization of the floppase was under-
taken.
 .The time-dependent inward movement flip of
NBD-PS to the inner membrane leaflet and its re-
 .verse movement to the outer leaflet flop at 378C are
shown in Fig. 1. By fitting exponential functions to
the kinetic data, rate constants and fractions of the
 .Fig. 1. Enhancement of translocation 378C of NBD-labeled PS
 .from the outer to inner membrane leaflet flip as well as
inhibition of its reverse translocation from the inner to the outer
 .  .leaflet flop by a pretreatment 15 min, 378C of cells with 0.2
mmol ly1 TPCK. For details see Section 2. Open and closed
triangles: flip and flop without pretreatment. Open and closed
circles: flip and flop for TPCK-pretreated cells. Results from a
characteristic flip and flop experiment out of a series of resp. 12
and 3.
probe in the inner membrane leaflet under stationary
 .conditions are obtained see Section 2 . The rate
 .  .constants for the flip k and flop k kinetics1 y1
from a series of experiments are 0.028"0.004 miny1
 .half times17 min; ns17 and 0.010"0.002
y1  .min half times25 min; ns35 . The stationary
levels of NBD-PS in the inner leaflet are 68.8"7.3%
 .  .ns35 following flip and 64.5"6.5% ns17
following flop and thus comparable.
The above-mentioned higher stationary level of a
spin-labeled PS probe is probably due to its 7-fold
y1 w xhigher flip rate, k s0.21 min 29 compared to1
0.028 miny1 for NBD-PS, since the flop rates for the
w xtwo probes are quite similar, k s0.012 29 andy1
0.010 miny1. In line with the idea that the levels of
PS probes in the inner membrane leaflet result from
the two opposite translocation processes via the flip-
pase and the floppase, the ratios of the rate constants
for the flip and flop of the spin-labeled PS and
 .NBD-PS 17.5 and 2.8 correlate with the stationary
distribution ratios of the probes between the inner
 .and the outer membrane leaflet 19 and about 2.0 .
The accumulation of NBD-PS in the inner leaflet
increases upon a lowering of temperature. At 158C,
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the stationary level of NBD-PS in the inner mem-
 .brane leaflet rises to 91% data not shown . This can
be explained by the lesser contribution of the flop-
pase, at the lower temperature, to the stationary dis-
tribution of the probe. Floppase activity has a steeper
 y1 w x.temperature dependence E s104 kJ mol ; 7a
 y1 .than the flippase E s20 kJ mol , data not shown .a
Pursuing this argument, selective inhibition of either
flippase or floppase activity should shift the station-
ary distribution of NBD-PS in favour of the outer or
inner membrane leaflet.
In the course of our investigations this expectation
turned out to be true. Several reagents were found to
shift the stationary distribution of NBD-PS in favour
of the inner membrane leaflet in parallel with an
increase of the flip rate. A pretreatment of cells with
w x wthe alkylating reagent 30 L-1-chloro-3- 4-tosyl-
x  y1amido -4-phenyl-2-butanone TPCK; 0.2 mmol l ,
.15 min, 378C , known as a protease inhibitor, en-
hanced the flip rate by a factor 1.5 to k s0.042"1
y1  .0.005 min ns12 and increased the accumula-
tion of NBD-PS in the inner membrane leaflet Fig.
.  .1 from 69% to 94.1"3.0% ns12 . Similar results
were obtained after a pretreatment of cells with 1-
 y1.chloro-2,4-nitrobenzene CDNB, 0.5–1.0 mmol l .
CDNB reacts with intracellular GSH catalyzed by
glutathione-S-transferase and produces 2,4-di-
 w x.nitrophenyl-S-glutathione DNP-SG 25 . The forma-
tion of this conjugate goes along with an increase of
the fraction of NBD-PS in the inner membrane leaflet
 .from 69 to 81.9"4.7% ns7 .
Besides these covalent modifications, treatment of
erythrocytes with reversibly binding compounds such
 y1 .as verapamil 50 mmol l ; Fig. 2 , dipyridamole,
 y1.indomethacin or prostaglandin A1 20 mmol l and
 y1.daunomycin or oligomycin 30 mmol l increased
the accumulation of NBD-PS in the inner membrane
 .leaflet from 69 to 86–94%, ns2, data not shown .
These higher accumulations of NBD-PS in the
inner leaflet by the various covalent and noncovalent
reagents were paralleled by variable increases of the
 .flip rate constant for NBD-PS Table 1 . Stimulation
of the flippase by reversibly binding drugs is not
responsible for the enhanced flip rate, since no signif-
icant flip enhancements by these compounds were
 .observed in TPCK-pretreated cells data not shown .
Considering the composite origin of the stationary
distribution of NBD-PS, the flip stimulations are
Fig. 2. Enhanced flip rate and accumulation in the inner mem-
 .brane leaflet of NBD-PS open circles and simultaneous inhibi-
 . y1tion of its flop solid circles by addition of 50 mmol l
verapamil during the translocation measurement at 378C. The
dotted lines represent the flip and flop kinetics in the absence of
 .verapamil 378C . Results from a characteristic experiment out of
a series of 3 at the same concentration.
likely to arise from an inhibitory effect on the flop
process. This could indeed be demonstrated. The flop
of NBD-PS proved to be strongly inhibited 95%,
.  .ns3 by a pretreatment of cells with TPCK Fig. 1 ,
CDNB, and other alkylating reagents, L-1-chloro-3-
w x  .4-tosylamido -7-amino-2-heptanone TLCK and
 .ethacrynic acid Table 1 . Moreover, the flop was
suppressed by the presence, during the measurement,
 .of cationic drugs such as verapamil Fig. 2 , vinblas-
tine, colchicine, vincristine, quinidine and stau-
rosporine as well as of anionic drugs such as indo-
methacin, ethacrynic acid, monensin, benzbromarone,
 .carbonyl cyanide m-chlorophenylhydrazone CCCP
 .and genistein Table 1 .
To substantiate that this inhibition of the flop
process is really due to inhibition of the floppase
rather than a stimulation of the flippase, the NBD-PS
flop was measured in the presence of albumin in the
 y1.medium 0.75 g dl at 1.5% hematocrit. This pro-
vides for a continuous extraction of the probe from
the outer membrane leaflet, which keeps the concen-
tration of the probe in this leaflet during the flop very
 w x.low zero-trans flop 28 and thereby excludes con-
tributions of a flippase-mediated inward movement of
NBD-PS to the flop kinetics. As shown in Fig. 3,
TPCK and CDNB strongly inhibit the outward
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Table 1
 .Effects of various drugs on the floppase-mediated translocation of NBD-PS or -PC , the flippase-mediated translocation of NBD-PS and
the efflux of DNP-SG
y1 .Drug Concentration mmol l krk0
 .Flop of NBD-PS -PC Flip of NBD-PS Efflux of DNP-SG
None 1.00 1.00 1.00
 .Dipyridamole 20 0.05 0.26 1.26 0.53
 .Verapamil 50 0.10 0.29 1.17 0.91
Vinblastine 50 0.25 1.00 0.89
Colchicine 50 0.71 1.00 1.00
Quinidine 50 0.70 1.14 1.0
 .Daunomycin 15–30 0.05 0.11 1.05
Staurosporine 20 0.05 1.12
Vincristine 50 0.05 0.90
 .Monensin 50 0.15 0.47 1.00 0.75
Rose bengal 20 0.71 0.66 0.57
 .Indomethacin 30 0.09 0.22 1.00 0.42
 .Genistein 150 0.32 0.46 1.00 0.44
Phloretin 250 0.28 1.07 0.27
Hexanoate 50,000 1.00 0.55
Salicylate 20,000 0.43 0.21
Benzbromarone 20 0.19 0.52
 .Ethacrynic acid 50 0.05 0.10 1.14 0.77
CCCP 30 0.16 0.48 0.75
SDS 50 0.47 0.54
 .Oligomycin 30 0.24 0.38 1.26 0.44
Triton X-100 150 0.33 1.00 0.68
a  .CDNB 1000 0.12 0.05 1.06
b  .TPCK 200 0.05 0.20 1.56 0.73
b  .TLCK 500 0.05 0.05 1.55 0.88
PCMBSc 100 0.45 0.69
 .The rate constants for the translocations mediated by the flippase and floppase as well as the DNP-SG efflux in the presence of drug k
 .were related to those in their absence k . The rate constants for the floppase-mediated component of translocation were obtained from0
 .the difference of the rate constants for the total flop and the leak flop k . The leak flop was determined after inhibition of the floppaseleak
y1  . y1 w xby addition of 1 mmol l vanadate or by pretreatment 15 min, 378C of cells with 0.8 mmol l N-ethylmaleimide 7 . The mean
 .  . y1 w xvalues of k for 18:1,6-NBD-PC and PS at 378C are 0.0028"0.0012 ns12; this work and 0.0007"0.0004 min 28 . Theleak
effects of drugs on the floppase were routinely measured using NBD-PS as a substrate. In some cases, given in brackets, 18:1,6-NBD-PC
was used. Data for the flip and flop of NBD-PS are mean values from resp. 2–12 and 2–7 experiments, data for the flop of NBD-PC and
the DNP-SG efflux are mean values from 1–2 experiments.
a,b,cPretreatment with the reagent for 30, 15 and 5 min, respectively at 378C.
translocation of NBD-PS under these conditions, too.
This proves that they really induce inhibition of
floppase activity.
Floppase inhibition by the noncovalent drugs could
also be confirmed using another phospholipid probe,
NBD-PC containing an oleoyl and a 6- NBD-
.  .amino hexanoyl residue 18:1,6-NBD-PC . The out-
ward flop kinetics of this probe, measured as usual in
 .the absence of albumin equilibrative flop , are not
greatly affected by the passive flip rate of NBD-PC,
w xwhich is very slow 7 , and thereby end up in a low
stationary level of NBD-PC in the inner leaflet 25%
w x.inside 7 . Presence during the flop of prostaglandin
 .A1, ethacrynic acid Fig. 4 , indomethacin, genistein,
monensin, benzbromarone, verapamil, daunomycin,
 .dipyridamole, and oligomycin Table 1 strongly sup-
presses the flop of NBD-PC. Similar results were
obtained with another NBD-labeled PC containing a
 .saturated myristoyl and a 12- NBD-amino lauroyl
 .  .residue 14:0,12-NBD-PC data not shown . Flop-
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Fig. 3. Inhibition of the flop of NBD-PS by a pretreatment of
cells with TPCK and CDNB. Flop in untreated cells open
.  y1circles and in cells pretreated with TPCK 0.2 mmol l , 15
.  .  y1 .min, 378C solid circles or CDNB 1 mmol l , 30 min, 378C
 .  .triangles was measured 1.5% hematocrit, 378C under zero-
trans conditions, i.e., by continuously removing the probe from
 y1.the outer leaflet by the presence of albumin 0.75 g dl in the
medium during flop. Results from characteristic experiments out
of a series of 3 for the same pretreatments.
pase inhibition is therefore responsible for the en-
hancement of the inward translocation rate and con-
comitant higher accumulation in the inner leaflet of
NBD-PS after pretreatment of cells with TLCK,
TPCK or CDNB and by various anionic and cationic
 .drugs Table 1 .
In contrast to this strong and rather unselective
inhibition of the floppase, the aminophospholipid
flippase is not affected by the cationic drugs studied
 .Table 1 . Among the anionic drugs tested, some are
without effect on the flippase although being strong
inhibitors of the floppase activity, while others have
at least a moderate inhibitory effect. This is true for
 y1. salicylate 79% at 20 mmol l , CCCP 52% at 30
y1.  y1.mmol l , 2,4-dinitrophenol 43% at 2 mmol l ,
 y1. benzbromarone 48% at 20 mmol l , SDS 53% at
y1.  y1.50 mmol l and hexanoate 45% at 50 mmol l
 .mean values for 2 experiments . The anionic phos-
phodiester, glycerophosphoserine, which has recently
w xbeen claimed 31 to suppress the flippase in studies
using an indirect test, proved to be ineffective. In our
hands, the flippase-mediated translocation of NBD-PS
measured by the albumin extraction procedure see
.Section 2 was not inhibited by glycerophosphoserine
y1  .at 0.5 mmol l data not shown . A short pretreat-
 . ment 5 min of cells with low concentrations 0.1
y1. w xmmol l of the highly impermeable 32 sulfhydryl
 .reagent, p-chloromercuribenzoate PCMBS , inhib-
 .ited the floppase by about 55% ns2; Table 1 . This
demonstrates the functional importance of an exofa-
cial SH-group on the floppase. The same modifica-
tion produced a lower inhibition of the flippase ns
.2; Table 1 .
The different inhibitor sensitivities of the flip and
flop process and also the different activation energies
reported above make it very unlikely that both pro-
cesses are mediated by the same protein.
Previously, we have presented evidence for a pro-
tein-mediated outward translocation of diacyl-PC
synthesized from endogenous lysoPC by acylation
with exogenous long-chain fatty acids at the inner
w xsurface of the erythrocyte membrane 4 . This translo-
cation was fast, in contrast to the slow outward
w xtranslocation of newly synthesized PE 4 . A similar
substrate specificity has not been observed for the
floppase-mediated translocation of NBD-phospholi-
w xpids 6,7 . Moreover, the activation energy for the
outward translocation of newly synthesized PC 30 kJ
y1 w x.mol 4 was considerably lower than that of NBD-
PC. Therefore, both processes are unlikely to be
related.
Fig. 4. Inhibition of the flop of 18:1,6-NBD-PC by addition of
prostaglandin A1, ethacrynic acid and MK 571. Flop was mea-
 .sured at 378C in the absence open circles and presence of 20
y1  . y1mmol l prostaglandin A1 solid circles , 100 mmol l
 . y1  .ethacrynic acid up triangles or 5 mmol l MK 571 squares .
Results from characteristic experiments out of a series of 2–3
experiments at the same concentrations.
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As proposed above, the inhibitory effect of the
CDNB treatment on the floppase activity might be a
consequence of the formation of DNP-SG. An inhibi-
tion of 50% was obtained after conjugation of about
y1 500 mmol glutathione l of packed red cells data
.not shown . Glutathione conjugates are removed from
erythrocytes by two active transport activities, one
with high affinity and another one with low affinity
for DNP-SG, also termed human multispecific or-
 .ganic anion transporters hMOAT3 and hMOAT4 .
They have different substrate specificities and sensi-
tivities towards inhibition by organic anions
w x14,16,33 . Both activities have the capacity to medi-
ate the efflux of glutathione conjugates, mercap-
w xturates, organic anions, as well glucuronides 16,33 .
There is growing evidence that the high affinity
w xpump for glutathione conjugates is identical 17,34,35
with the multispecific transport protein associated
 .with the development of multidrug resistance MDR
 .and termed multidrug resistance protein MRP , a
190-kDa protein belonging to the ATP-binding cas-
 . w xsette ABC transporters 36–38 . The MRP1 isoform
of the MRP family has been identified in tissue cells
w x w x34 as well as erythrocytes 17 while MRP2 is the
isoform predominantly present in the hepatic canalic-
w xular membrane 39 . MRP has a very broad substrate
specificity and not only transports anionic conjugates
of drugs with glutathione, glucuronate and sulfate but
also unmodified lipophilic cytotoxic anionic, neutral
w xand cationic drugs 40–44 . If inhibition of the flop-
pase-mediated translocation of NBD-phospholipids by
CDNB would be due to the formation of DNP-SG,
incubation of CDNB-pretreated cells should result in
the removal of DNP-SG from the cells and thereby in
a time-dependent loss of its inhibitory effect on
translocation. This could indeed be demonstrated.
Following a CDNB pretreatment of cells producing
50% inhibition of translocation, subsequent incuba-
tion of cells for 17 h at 378C in the presence of
 y1 .energy supply 5 mmol l inosine decreased inhibi-
 .tion to below 10% data not shown . Moreover, a
direct inhibitory effect of DNP-SG on the floppase
could be demonstrated in resealed ghosts containing
various concentrations of DNP-SG, the glutathione
 . conjugate of ethacrynic acid EA-SG or GSSG Fig.
.5 . Data for the ratio of the rate constants in the
 .  .absence k and presence k of drug from 3 to 50
experiments were plotted against the drug concentra-
Fig. 5. Inhibition of the flop of 18:1,6-NBD-PC by trapping of
DNP-SG, EA-SG or GSSG within resealed ghosts. After lysis of
 .erythrocytes in a solution containing no additive open circles ,
y1  . y1 300 mmol l DNP-SG squares , 150 mmol l EA-SG trian-
. y1  .gles or 4 mmol l GSSG closed circles , resealed ghosts were
 .prepared and flop measured at 378C see Section 2 for details .
Results from characteristic experiments out of a series of 2
experiments at the same concentrations.
 .tions Dixon plot and the concentrations required to
 .obtain 50% inhibition IC of the flop of NBD-50
labeled PS and PC were derived. The IC values50
were 100 mmol ly1 for DNP-SG, 70 mmol ly1 for
EA-SG and 2 mmol ly1 for GSSG. Since GSSG is a
substrate for the high affinity pump for glutathione
w xconjugates 14,43 but is neither a substrate nor in-
w xhibitor for the low affinity pump 14 , these results
strongly suggest an involvement of the high affinity
pump, i.e., MRP, in floppase activity. Further support
for a role of MRP in floppase activity represents the
dependence of both activities on GSH. Essentially no
outward translocation of NBD-phopholipids was ob-
served in the absence of GSH within the resealed
 .ghosts data not shown . GSH concentrations within
the ghosts of 4–8 mmol ly1 are required to get flop
 .kinetics similar to those for cells cf. Figs. 4 and 5 .
Such a GSH-dependent transport has been reported
for the transport of certain cationic drugs by MRP
w x41,44–47 .
To exclude an involvement of the low affinity
pump for glutathione conjugates in the floppase-
mediated translocation of NBD-phospholipids, effects
of inhibitors of the floppase on this pump were
measured in erythrocytes. Under our experimental
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conditions, the concentration of DNP-SG 500 mmol
y1 .l or higher is well above the K value of the highm
affinity, low capacity transport system 3–4 mmol
y1 w x.l 14,33 and its transport will take place predomi-
nantly via the low affinity, high capacity transport
 y1 w x.system K s1 mmol l 14,33 . As shown inm
Table 1, the release of DNP-SG from the cells is only
slightly inhibited after their pretreatment with TPCK
or TLCK and by the presence during transport mea-
surement of verapamil, vinblastine, monensin,
ethacrynic acid or CCCP. In contrast, the floppase is
 .strongly inhibited by these treatments Table 1 .
Moreover, the temperature dependence for the low
affinity transport system is considerably lower 61 kJ
y1 w x.mol 33 than that of the NBD-phospholipid flop-
 y1 w x.pase 104 kJ mol 7 . Finally, the low affinity
pump is not affected by GSSG up to 12 mmol ly1
w x14 , whereas the floppase is strongly inhibited at 2–4
y1  .mmol l Fig. 5 . It is concluded that the transloca-
tion system mediating NBD-phospholipid flop is cer-
tainly different from the low affinity pump for glu-
 .tathione conjugates MOAT4 .
Further experiments aimed at collecting more evi-
dence for a role of MRP in floppase activity and
against such a role of another pump involved in
multidrug resistance and member of the ABC family,
w xthe 170 kDa MDR1 P-glycoprotein 48,49 . P-glyco-
protein is present in tumor cells and in the apical
membrane of epithelial cells but has not been identi-
fied in the erythrocyte membrane as yet. In human
cells, two classes of related P-glycoproteins ex-
pressed by the MDR1 and MDR2 gene were identi-
w xfied 22 . The MDR1 P-glycoprotein transports un-
wcharged and cationic hydrophobic drugs 19–
x22,40,50–52 and was the first identified protein
involved in multidrug resistance. Recently, MDR1
P-glycoprotein has been shown to transport NBD-
w xlabeled phospholipids, too 53–55 . On the other
hand, the MDR2 P-glycoprotein does not transport
drugs, but selectively transports PC in the canalicular
w xmembrane of hepatocytes 56,57 . It seemed therefore
of interest to check whether floppase activity shares
functional properties with P-glycoprotein.
This was done by studying the concentration-de-
pendent effects, on the floppase-mediated transloca-
tion of NBD-phospholipids, of various drugs known
w xto suppress MRP 18,40–43 and MDR1 P-glyco-
w xprotein 19–22 activity. Data for the ratio of the flop
 .  .rate constants in the absence k and presence k of0
drug from 2 to 5 experiments were plotted against the
drug concentrations and the concentrations required
 .to obtain 50% inhibition IC of the flop of NBD-50
labeled PS and PC were derived. The IC values for50
verapamil, vinblastine and oligomycin were similar
 . w xTable 2 to those reported 22,40,58 for both the
MRP protein and the MDR1 P-glycoprotein. On the
other hand, the IC values for the floppase inhibition50
by anionic drugs such as genistein, indomethacin,
CCCP, benzbromarone, prostaglandin A1 and
 .ethacrynic acid are considerably lower Table 2 than
those reported for the MDR1 P-glycoprotein pump
w x40,58,59 . They were, however, similar to those
w xestablished for the MRP pump 18,40,42,59,60 . An-
w xother potent, competitive inhibitor of MRP 17,43,61 ,
the anionic leukotriene D receptor antagonist MK4
w x w x571 24 , which does not affect P-glycoprotein 61 ,
 .strongly inhibited floppase activity Fig. 4 . At 5
mmol ly1 MK 571, the inhibition of the flop of
18:1,6-NBD-PC, 14:0,12-NBD-PC and NBD-PS were
65–70% in erythrocytes. The concentration of MK
571 required to obtain 50% inhibition of the floppase
y1  .activity was 2.2 mmol l for NBD-PS ns3 ,
Table 2
Drug concentrations required for 50% inhibition of the activities
of floppase, MRP and MDR1
y1 .Drug IC mmol l50
a b bFloppase MRP MDR1
Oligomycin 5 1–2 1–2
Vinblastine 10 2–5 2–3
Verapamil 5–10 4–8 2–5
Ethacrynic acid 20 20–30 )800
Indomethacin 5 10–20 )800
Genistein 100 150–200 )1,000
CCCP 10 10–30 )200
Prostaglandin A1 5 3–5 )100
Benzbromarone 5–10 5–10 )500
aThe concentrations of the drugs required to obtain 50% inhibi-
tion of the floppase-mediated outward translocation of NBD-
labeled PS or 18:1,6-NBD-PC were derived from a Dixon plot of
the ratio of the flip rate constants in the absence and presence of
 .drug against drug concentration 2–5 experiments .
b w xData taken from Ref. 40 represent the concentrations of the
drugs required to obtain 50% inhibition of the efflux of calcein
acetoxymethyl by MDR1 and MRP expressed in human tumor
cells.
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y1  .2.4 mmol l for 14:0,12-NBD-PC ns1 and
y1  .2.7 mmol l for 18:1,6-NBD-PC ns2 and thereby
w xquite similar to that for MRP 17,43,61 . As shown
above for other inhibitors of the floppase, the station-
ary distribution of NBD-PS following flip was also
 .increased by addition of MK 571 data not shown .
The close correlations between the inhibitory ef-
fects of various drugs on the floppase and MRP as
well as the inhibition of the floppase by glutathione
conjugates and GSSG trapped within resealed ghosts
strongly suggest that the floppase mediating the
translocation of NBD-phospholipids in the erythro-
cyte membrane is in fact the MRP pump. This func-
tion of MRP as a floppase for NBD-phospholipids
may overlap with its physiological role of extruding
toxic substances from the cell. Recently, the ether
analog of PC, 1-O-octadecyl-2-O-methyl-glycero-3-
phosphocholine, was identified by indirect methods
as a substrate for several ABC transporters including
w xMRP expressed in yeast 62 . The acceptance of a
phospholipid by MRP may depend on the presence of
an unphysiological hydrophobic group such as NBD
or a short fatty acyl chain on the phospholipid
molecule. It remains to be seen to what extent MRP
 .MOAT3 also accepts phospholipids with two long
acyl chains. From the high membranerwater parti-
tion coefficients of the NBD-phospholipids about
5 .10 ; data not shown , a primary association of NBD-
phospholipid with the floppase from the aqueous
phase is unlikely. Therefore, MRP like MDR1 and
MDR2 may act as a real floppase, i.e., as a trans-
porter binding its substrate from the inner membrane
leaflet and moving it to the outer leaflet. Depending
on the lipid solubility, substrate binding could take
place variably from either the membrane lipid bilayer
or the aqueous medium. This would then correspond
to the action of a classical exchanger of hydrophilic
anions, band 3, that has been reported to operate as a
translocase for membrane-associated anionic lipids
w x11–13 . Translocation of NBD-phospholipid via an-
other mechanism, i.e., extraction of the probe from
the inner membrane lipid leaflet and extrusion into
the external aqueous medium, the so-called action as
w xa vacuum cleaner 63,64 , cannot be excluded, since
the NBD-phospholipid released into the external
aqueous medium would immediately redistribute into
the outer membrane leaflet due to its high mem-
branerwater partition coefficient.
Recently, MDR1 P-glycoprotein has been sug-
gested to accept zwitterionic NBD-labeled phospho-
 . w xlipids PC and PE , but not the anionic NBD-PS 55 .
This exclusion of PS corresponds to the established
specificity of the MDR1 P-glycoprotein for neutral
w xand cationic substrates 20–22 . On the other hand,
MRP has been reported to transport neutral and
w xcationic as well as anionic substrates 40–43 . As-
suming that the floppase for NBD-phospholipids is
really identical with MRP1, it is not surprising that it
translocates mono- and di-anionic as well as zwitteri-
w xonic NBD-phospholipids 6,7 .
In studies on the kinetics and stationary distribu-
tions of NBD-labeled phospholipids as probes for
endogenous phospholipids of cell membranes, the
presence of MRP-mediated outward translocation
should be considered.
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